Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
NCT ID NCT07733050
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding an immunotherapy drug (serplulimab) and a targeted antibody (bevacizumab) to standard chemotherapy can help people with metastatic pancreatic cancer that has progressed after initial treatment. The study enrolls about 34 adults whose cancer has spread and who have already tried one prior therapy. Researchers are measuring overall survival and tumor response to see if this combination offers a benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- serplulimab, bevacizumab, and chemotherapy (FOLFIRINOX or NALIRIFOX)
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with metastatic pancreatic cancer, potentially improving survival.
- What could go wrong
- This is an early-phase, single-arm trial with only 34 participants, so results may not be generalizable. The combination also carries risks of serious side effects from immunotherapy and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart drug delivers chemo directly to pancreatic cancer cells
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
- Could a stomach drug help fight pancreatic cancer?
- New hope for tough pancreatic cancer? drug combo targets KRAS mutations
- Experimental vaccine combo takes on tough pancreatic cancer
- Supercharged immune cells take on Hard-to-Treat pancreatic cancer